Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of composition of micromolecular fucoidan and fucoxanthin to preparation of composition for improving nonalcoholic steatohepatitis (NASH)

A molecular fucoidan and molecular fucoidan technology, which can be used in medical preparations containing active ingredients, drug combinations, organic active ingredients, etc., can solve inconclusive, unable to find non-alcoholic fatty liver, obesity and bladder cancer and other problems, to achieve the effect of improving expression, improving insulin resistance, and reducing liver fat coefficient

Pending Publication Date: 2020-12-25
HI Q MARINE BIOTECH INT +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Compared with alcoholic fatty liver caused by long-term drinking (more than 50 grams of alcohol per day), non-alcoholic fatty liver is more likely to occur in patients with lipodystrophy, diabetes, obesity, etc., and it is more accompanied by hyperlipidemia and hyperglycemia In clinical research, it is also found that diabetic patients or obese people (with high BMI) are high-risk groups of non-alcoholic fatty liver, and when the state of non-alcoholic fatty liver continues, there are many in the natural course of the disease. High probability leads to nonalcoholic steatohepatitis (NASH), and nonalcoholic steatohepatitis plays an important role in liver fat fibrosis. However, so far, its related mechanism and cause are still inconclusive. Among them, Studies have shown that diabetic patients with fatty liver have a higher chance of developing non-alcoholic steatohepatitis than those with simple fatty liver
[0004] Although the research on non-alcoholic fatty liver is in full swing all over the world, many hypotheses and possible mechanisms are constantly being updated, and many possible treatment methods have been proposed in cell and animal experiments, but they are rarely used in humans. In clinical trials; according to the existing technology, in human experiments, although Pioglitazone, a currently marketed diabetes drug, can improve liver function, it has the risk of obesity and bladder cancer, while Liraglutide can help lose weight, but it needs subcutaneous injection , so it is still impossible to find a non-toxic and non-alcoholic fatty liver improvement method that can be used in humans

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of composition of micromolecular fucoidan and fucoxanthin to preparation of composition for improving nonalcoholic steatohepatitis (NASH)
  • Application of composition of micromolecular fucoidan and fucoxanthin to preparation of composition for improving nonalcoholic steatohepatitis (NASH)
  • Application of composition of micromolecular fucoidan and fucoxanthin to preparation of composition for improving nonalcoholic steatohepatitis (NASH)

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0029] Preparation Example 1 Preparation of a Composition Containing Small Molecule Fucoidan and Fucoxanthin

[0030] The purpose of this example is to prepare a composition containing small molecule fucoidan and phycoxanthin, which is prepared in the following manner. After cleaning the brown algae raw materials and reducing the heavy metal content, they are extracted according to the existing method to obtain fucoxanthin and small molecule fucoidan, and then sterilized. In the ratio of 1 to 1, 550 mg was weighed and filled to form a capsule to complete the composition containing small molecule fucoidan and fucoxanthin; among them, the small molecule fucoidan and fucoxanthin capsules are from the sea Biotechnology Co., Ltd., and the molecular weight of small molecule fucoidan is between 500 daltons and 1000 daltons.

Embodiment 1

[0031] Example 1 Administering a composition containing small molecule fucoidan and phycoxanthin to a subject and measuring fatty liver, liver fibrosis and metabolic indicators

[0032]The subjects had been diagnosed with fatty liver by abdominal ultrasound, and had non-alcoholic fatty liver disease, and were not taking vitamin E, Pioglitazone or injecting Liraglutide. The subjects were randomly divided into two groups in a double-blind test. The first group took the capsules containing the composition of small molecule fucoidan and phycoxanthin prepared in Preparation Example 1. The experiment lasted for 6 months and took 6 capsules (each containing 275 mg of small molecule fucoidan and 275 mg of fucoxanthin), divided into 3 capsules in the morning and 3 capsules in the evening, as the experimental group; the second group took placebo capsules composed of cellulose, The same experiment lasted for 6 months, taking 6 pills a day, divided into 3 pills in the morning and 3 pills ...

Embodiment 2

[0033] Example 2 Effects of the composition containing small molecule fucoidan and phycoxanthin on the subjects' fatty liver, liver fibrosis and metabolic indicators in the first test

[0034] According to the experimental method of Example 1, the age, BMI, fasting blood glucose, total cholesterol, high-density lipoprotein, low-density lipoprotein, uric acid, creatinine, aspartate aminotransferase, and Alanine aminotransferase index, liver stiffness, fatty liver value, glycosylated hemoglobin, triglyceride, adiponectin, leptin and insulin, as shown in Table 1, fatty liver coefficient (CAP) shows the fatty liver of the experimental group Slightly more serious than the control group, but from the final experimental results described later, the experimental group has a better auxiliary improvement effect than the control group, and the rest of the values ​​have no statistical difference, so as to establish the randomness of the experimental grouping .

[0035] Table 1 Fatty live...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Average molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to application of a composition of micromolecular fucoidan and fucoxanthin to preparation of composition for improving nonalcoholic steatohepatitis (NASH), in particular to application of the composition of the micromolecular fucoidan and the fucoxanthin to preparation of the composition for improving the NASH. The composition can achieve the purpose of improving the NASH byimproving the fatty liver coefficient and blood biochemical parameters of serum alanine transaminase (ALT), ante cibum glucose (AC) and glycosylated heme (HbAlc).

Description

technical field [0001] The present invention relates to a use, in particular to the use of the composition of small molecule fucoidan and phycoxanthin for improving non-alcoholic fatty liver. Background technique [0002] Non-alcoholic fatty liver and alcoholic fatty liver belong to the clinical classification of fatty liver. Fatty liver is clinically defined as the fat content in the liver exceeding 5% of the total liver weight, or 1% in liver tissue sections Ten out of ten cells present degenerated fat vacuoles, which is one of the civilized diseases of modern people, and it has been considered one of the main liver diseases by most developed countries, including Europe and the United States. Non-alcoholic fatty liver and alcoholic fatty liver are only distinguished clinically, and the causes are also different. However, pathological signs such as fatty disease, steatohepatitis, liver fibrosis and even liver cirrhosis can be found . [0003] Compared with alcoholic fatty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/702A61K31/715A61K31/336A61P1/16
CPCA61K31/702A61K31/715A61K31/336A61P1/16A61K2300/00
Inventor 吴明顺
Owner HI Q MARINE BIOTECH INT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com